SUMMARY Because thrombocytopenia occurs frequently in patients with anticardiolipin (aCL) antibodies and thrombosis, some investigators have proposed that aCL antibodies may play a direct part in thrombosis by binding and activating platelets. To test this proposal experiments were performed to determine whether aCL antibodies can bind platelets. Preincubation of aCL positive sera with freeze-thawed platelets caused significant inhibition of aCL activity in four serum samples tested. Antibodies with cardiolipin binding activity were subsequently eluted from these platelets. Total phospholipids extracted from platelets inhibited aCL activity, and the specific phospholipids bound were shown to be phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol. It is concluded that aCL antibodies can bind phospholipids in platelet membranes but pertubation of the membrane must first occur.
*These data were presented in part at the American Rheumatism Association meeting in Washington DC, USA, June 1987. aPL antibodies can bind platelets in vitro and to identify the components of the platelet membranes bound by these antibodies.
Patients and methods

PATIENTS
Serum samples from four patients with high aCL antibody levels were selected for study. Two of these four patients fulfilled the revised American Rheumatism Association criteria for systemic lupus erythematosus,6 and two were classified as having the 'antiphospholipid syndrome',7 8 Three of the four patients had a history of thrombosis, two had thrombocytopenia (platelet count <100x 109/1), and three had a positive Coombs' test. All four patients had a positive lupus anticoagulant test. One patient had IgG aCL antibodies, one patient IgM, and the remaining two patients had both IgG and IgM aCL antibodies. collected in citrate phosphate dextrose (CPD) adenine 1 and units of whole blood collected in CPD anticoagulant were used for study.
Twenty millilitre aliquots of platelet concentrates were centrifuged at 1500 g for 20 minutes at room temperature. The supernatant was discarded and the pellets were washed three times in phosphate buffered saline (PBS) pH 7.4 by centrifugation at 1500 g for 10 minutes each time. The washing procedure was monitored by light microscopy. The final platelet preparations did not contain more than one erythrocyte or leucocyte per 50 high power fields.
Twenty millilitre aliquots from a whole blood sample were centrifuged at 300 g for 20 minutes, following which the supernatant plasma, leucocyte, and platelet layers were removed and discarded. The red cells were then washed three times by suspension in PBS.
The final concentrations of platelets and erythrocytes were estimated by Coulter Counter model S-plus IV and adjusted to 2x109/ml. The washed platelets and erthrocytes were stored in small aliquots (1 ml) at -20°C until further use. Partially disrupted platelets and erythrocytes were obtained by freeze-thawing three times. Sonicated platelets were prepared by sonicating twice with a Soniprep 150 (MSE) sonicator, on ice, for three minutes each time with one minute intervals.
ISOLATION OF a,CL ANTIBODIES USING PLATELETS
Ten millilitre aliquots of serum with high aCL binding activity were mixed with 5 ml of freezethawed platelets prepared as described previously. The mixture was incubated at 37°C for one hour and overnight at room temperature with constant mixing. The mixture was then centrifuged at 25 000 g for one hour and the supernatant removed. The pellet was resuspended in 10 ml of PBS and thoroughly washed. The mixture was again centrifuged at 25 000 g for 30 minutes and the supernatant removed. This washing procedure was repeated three times. After the third wash the pellet was resuspended in 2 ml of 1-5 M potassium iodide and incubated for one hour with constant mixing to elute antibodies bound to platelet membranes. The preparation was centrifuged at 25 000 g for 15 minutes and the pellet discarded. (Fig. 3) . The eluate obtained from the serum of the patients with IgM aCL activity had only IgM, 
and the eluates from the two serum samples with IgG and IgM aCL activities had both IgG and IgM immunoglobulins. Eluted preparations from platelets also contained significant quantities of albumin. Each of the four eluted preparations had cardiolipin binding activity and the binding activity of each preparation was confined to the same isotype as that of the serum from which the preparation was obtained.
IDENTIFICATION OF COMPONENTS OF PLATELET MEMBRANE BOUND BY aCL ANTIBODIES
Two aCL positive sera were preincubated with total phospholipids extracted from platelets and inhibition of cardiolipin binding activity determined. In both instances total platelet phospholipids inhibited cardiolipin binding activity to an extent similar to that observed using freeze thawed platelets.
The total platelet phospholipid extract was separated into its individual components by HPTLC and inhibition of cardiolipin binding activity by each of the separated components examined. The phospholipid components identified were phosphatidylethanolamine (PE), sphingomyelin (SPH), phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylinositol (PI). PE, PS, and PI all inhibited cardiolipin binding activity, but SPH and PC caused little or no inhibition (Fig. 4) The present study was designed to determine whether aCL antibodies bind platelet membranes and to identify the membrane components bound by these antibodies. We found that preincubation of aCL positive sera with 'intact' platelets caused little inhibition of cardiolipin binding activity, but preincubation with freeze-thawed or sonicated platelets resulted in greater than 50% inhibition of cardiolipin binding activity. Similar results were obtained with intact and freeze-thawed red blood cells. The similarity between results obtained with platelets and with red cells may be explained by the fact that the composition and probably the distribution of phospholipids in platelet and red blood cell membranes are similar.' Hence freeze-thawing probably results in exposure in both types of cells of phospholipids that can be bound by aCL antibodies. As far as is known, however, only platelet membranes undergo molecular rearrangements during the clotting process,4 therefore the present study was confined to platelets.
The observed inhibition of aCL activity by freeze 16 and presumably become exposed and accessible to aCL antibodies by freeze thawing. Anticardiolipin binding to platelet PE was unexpected. We have found previously, and confirmed in the present series of experiments, that preincubation of aCL positive sera with commercially obtained PE (bovine brain) does not result in inhibition of cardiolipin binding activity.1' It is possible that there may be subtle differences in the conformation of individual phospholipid molecules depending on their source and on the phospholipids with which they are mixed. 18 19 Recently, Rauch and colleagues using a monoclonal aPL antibody with lupus anticoagulant activity found that this antibody bound PE in one configuration but not another.20
It is well known that the lupus anticoagulant test can be 'bypassed' by addition of freeze-thawed or sonicated platelets, but the mechanism of this bypass phenomenon is not established.2' 22 One possibility is that the sonicated platelets provide an additional phospholipid template on which the prothrombin activator complex can form and this would enable bypass of the lupus anticoagulant activity, whatever the mechanism that accounts for this activity. An alternative explanation is that platelet membrane phospholipids exposed on sonication absorb aPL antibodies, so preventing these antibodies from blocking the prothrombin activator complex-phospholipid interaction. The findings of the present series of experiments show that the neutralisation reaction probably occurs because of the latter mechanism whereby aPL antibodies are absorbed out of plasma by platelet phospholipids.
The absence of binding of aPL antibodies to intact platelets in this study confirms a number of abstracted studies which show that lupus anticoagulant or aCL positive plasma have no effect on platelet function. 23 On the other hand, demonstration of binding to sonicated platelets suggests that if aPL antibodies cause thrombosis through a platelet mediated mechanism one must propose that partial activation of the platelet and exposure of target phospholipids must take place before antibody binding. Hence, owing to the observations reported here, we are currently performing experiments in our laboratories using partially activated rather than inactivated platelets. 
